Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases,...
Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101
Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China AC-101 demonstrated a favorable safety and PK/PD...
THE GLEN GRANT DEVOTION 70-YEAR-OLD SELLS FOR £81,250 ($101,300 USD) AT AUCTION WITH PROCEEDS TO BENEFIT THE ROYAL SCOTTISH FORESTRY SOCIETY
Sotheby's has completed the sale of the first of the seven total decanters, each one-of-a-kind, and housing an exquisite 70-year-old single malt whisky, the oldest release from The Glen Grant distillery. ROTHES, Scotland, Sept. 26, 2023 /PRNewswire/...
US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer
SEONGNAM, South Korea, July 21, 2023 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on July 19 that the US FDA had granted an orphan drug designation for small cell lung cancer for SNB-101 (API: SN-38), a new polymer...